Rialtris nazat spray. doses. susp. fl. 56 doses

Spray nasal Rialtris – antiedematous medicine for topical administration at nasal cavity diseases. A corticosteroid for treatment of seasonal allergic rhinitis.

Structure

• 1 dose supports an olopatadin of a hydrochloride of 665 mkg is equivalent to an olopatadin of 600 mkg and a mometazona of furoate of monohydrate is equivalent to a mometazon to furoate of 25 mkg;
• other components: cellulose microcrystalline and sodium carboxymethylcellulose; sodium hydrophosphate, heptahydrate; sodium carboxymethylcellulose; sodium chloride; benzalkoniya of chloride of 50% solution; benzalkoniya chloride; edetat dinatrium; polysorbate 80; Acidum hydrochloricum; sodium hydroxide; water for injections.

Contraindication

Hypersensitivity to an olopatadin to a hydrochloride, a mometazon of furoate or other components of medicine.

Presence of not treated localized infection of a mucous nasal cavity.

Route of administration

Adults and children of 12 years: the recommended dose makes 2 injections in each nasal course 2 times a day.

Feature of application

In clinical trials of the mometazon of furoate entered intranazalno in some cases observed development of the localized fungal infection of a nose and throats (Candida albicans). When developing a fungal infection use of the medicine Rialtris it is necessary to stop and begin the corresponding treatment. The patients using the medicament Rialtris within several months or longer have to have periodically examination on presence of an infection of Candida or other signs of an adverse effect on mucous a nose. In clinical trials of the medicine Rialtris the cases of an infection of Candida are not registered.

Pregnant

during pregnancy the medicament Rialtris should be used only if the expected advantage for the woman exceeds potential risk for a fruit.

Children

Are not present sufficient clinical experience of use of medicine to children up to 12 years therefore it should not be applied to patients of this age category.

Drivers

during the Rialtris medicament treatment of patients should warn about need to abstain from the work demanding the increased concentration of attention and speed of reactions, for example operation of mechanisms or control of motor transport.

Acute overdose by this dosage form it is improbable

as rolled into one the medicine Rialtris, intended for application within 30 days (240 doses), about 160 mg of a hydrochloride of an olopatadin and 6 mg of a mometazon of furoate contain.

Side effects

from nervous system: dysgeusia, dizziness, flabbiness, drowsiness, uneasiness, insomnia.

Infection and invasion: pharyngitis, respiratory infections.

from respiratory organs, a thorax and mediastinum: cough, dryness in a nose, discomfort in a nose, irritation of a throat, goose breathing.

from digestive tract: dryness in a mouth, discomfort in a stomach, vomiting.

from skin and hypodermic cellulose: rash, itch, contact dermatitis.

to Store

at a temperature above 25 °C.

not to freeze

.

you do not store

in the fridge.

to Store

out of children's reach.